The alarming increase in the incidences of cardiovascular disorders has contributed to rise in the demand for hemodynamic (blood) and cardiac monitoring devices across the globe. Disorders such as hypertension, hypercholesterolemia, and coronary heart diseases, among others, are monitored on a regular basis by physicians and patients using these hemodynamic and cardiac monitoring devices. Every year, cardiovascular diseases (CVDs) are becoming a major cause for over 4 million deaths in Europe.
Download PDF Brochure@ http://www.micromarketmonitor.com/contact/7075062137-download_pdf_brochure.html
Non-invasive/minimally invasive cardiac output monitoring devices are increasingly used on patients undergoing major or high-risk surgeries. For instance, the National Institute for Health and Care Excellence (NICE) advises the use of CardioQ-ODM, an oesophageal Doppler monitor, which is used in patients to assess the amount of blood pumped by the heart with each beat. It reduces the length of critical care and in-hospital stay for patients undergoing major or high-risk surgeries, further resulting in reduction of costs and post-operative complications.
Speak to Analyst @ http://www.micromarketmonitor.com/contact/7075062137-speak_to_analyst.html
In-depth profiling of the key players have been conducted, along with the recording of the recent developments (including new product launches, partnerships, agreements, collaborations, and joint ventures) and strategies adopted by the key players to sustain and strengthen their positions in the European non-invasive & minimally invasive cardiac output monitoring devices market. Edwards Lifesciences Corporation (U.S.), PULSION Medical Systems SE (Germany), Deltex Medical (U.K.), and LiDCO Group plc (U.K.) among the key players engaged in this market.
